Skip to content

Seeking Safety feasibility trial

Seeking Safety group intervention for complex post-traumatic stress disorder: a feasibility randomised controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN47207835
Enrollment
56
Registered
2026-06-18
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex post-traumatic stress disorder (CPTSD) Mental and Behavioural Disorders

Interventions

This is a feasibility trial of Seeking Safety. The objective is to test processes and gather information for the planning of a definitive randomised controlled trial (RCT) to evaluate Seeking Safety f

Sponsors

South West Yorkshire Partnership NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or over 2. Diagnosed with CPTSD or assessed as meeting the ICD-11 criteria 3. Receiving care from a CMHT or on a waiting list for psychological therapy in South West Yorkshire Partnership NHS Foundation Trust 4. Able to provide informed consent 5. Willing and able to attend a Seeking Safety group

Exclusion criteria

Exclusion criteria: 1. People with recurrent episodes of psychosis 2. People with a severe cognitive impairment 3. People currently receiving another psychological therapy for CPTSD or inpatient care 4. People assessed as posing a risk to other people in a group setting

Design outcomes

Primary

MeasureTime frame
Number of eligible people who consent to participate measured using Screening Log, study specific records and consent records at Screening/Pre-consent & Consent;Proportion of consented participants who complete baseline data and are randomised measured using Research data, screening log and randomisation records at Baseline & Randomisation;Proportion of participants completing end-of-treatment and follow-up assessments measured using Research data and withdrawal records at End of Treatment (6 months post randomisation), 12 months follow up;Proportion of participants completing the intervention (defined as attending at least 6 sessions) measured using Attendance records at Intervention period;Acceptability and feasibility of completing outcome measures measured using Qualitative interviews and research data at Interview period between End of Treatment (6 months post randomisation) and 12 Months follow up;Participants’ experience of Seeking Safety measured using Qualitative interviews at Interview period between End of Treatment (6 months post randomisation) and 12 Months follow up;Healthcare staff experience of delivering Seeking Safety measured using Qualitative interviews at Interview period between End of Treatment (6 months post randomisation) and 12 Months follow up;Control group tolerance of waiting for Seeking Safety measured using Qualitative interviews at Interview period between End of Treatment (6 months post randomisation) and 12 Months follow up

Secondary

MeasureTime frame
1. PTSD symptoms measured using Impact of Events Scale – Revised (IES-R), a 22-item self-report measure of subjective distress caused by traumatic events, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 2. Substance use measured using Leeds Dependence Questionnaire (LDQ), a 10-item self-report measure designed to assess dependence on a variety of substances, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 3. Mental wellbeing measured using Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), a widely used 14-item scale for assessing mental wellbeing in the general population, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 4. Social functioning measured using Work and Social Adjustment Scale (WSAS), a 5-item measure assessing the impact of mental health on day-to-day functioning, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 5. Health-related quality of life measured using EQ-5D-5L, a 5-domain tool with an additional self-rated health assessment, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 6. Capability wellbeing measured using ICEpop CAPability Instrument for Adults (ICECAP-A), a 5-item tool assessing wellbeing and quality of life, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 7. Service use measured using a modified version of the Client Services Receipt Inventory (CSRI), adapted for this study to assess service use, at baseline, end of treatment (6 months post randomisation) and 12 months follow up 8. Life events measured using the List of Threatening Experiences (LTE-Q), a 12-item tool assessing the impact of significant life events, at end of treatment (6 months post randomisation) and 12 months follow up

Countries

England, United Kingdom

Contacts

Public ContactKasia Malczuk
kasia.malczuk@swyt.nhs.uk+44 1924 316 289

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026